Profile image
Postdoctoral Fellow

Dr Anouschka Akerman

Bachelor of Science, First Class Honours (2014), UNSW

PhD in cancer therapeutics and stromal cell metabolism (2019), UNSW

Phone
+61-2-9348 0687
E-mail
aakerman@kirby.unsw.edu.au
Troelnikov A; Armour B; Putty T; Aggarwal A; Akerman A; Milogiannakis V; Chataway T; King J; Turville SG; Gordon TP; Wang JJ, 2023, 'Immunoglobulin repertoire restriction characterizes the serological responses of patients with predominantly antibody deficiency', Journal of Allergy and Clinical Immunology, 152, pp. 290 - 301.e7, http://dx.doi.org/10.1016/j.jaci.2023.02.033
2023
Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG, 2023, 'Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level', eBioMedicine, 90, http://dx.doi.org/10.1016/j.ebiom.2023.104545
2023
Poumbourios P; Langer C; Boo I; Zakir T; Center RJ; Akerman A; Milogiannakis V; Aggarwal A; Johnstone BA; Ha J; Coulibaly F; Turville SG; Drummer HE, 2023, 'Enhanced stability of the SARS CoV-2 spike glycoprotein following modification of an alanine cavity in the protein core', PLoS Pathogens, 19, http://dx.doi.org/10.1371/journal.ppat.1010981
2023
Shen Y; Freeman JA; Holland J; Solterbeck A; Naidu K; Soosapilla A; Downe P; Tang C; Kerridge I; Wallman L; Van Bilsen N; Milogiannakis V; Akerman A; Martins Costa Gomes G; Sandgren K; Cunningham A; Turville S; Mulligan SP, 2022, 'COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity', British Journal of Haematology, 197, pp. 41 - 51, http://dx.doi.org/10.1111/bjh.18014
2022
Shen Y; Freeman JA; Holland J; Naidu K; Solterbeck A; Van Bilsen N; Downe P; Kerridge I; Wallman L; Akerman A; Aggarwal A; Milogiannakis V; Martins Costa Gomes G; Doyle CM; Sandgren KJ; Turville S; Cunningham AL; Mulligan SP, 2022, 'Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion', Blood, 140, pp. 2709 - 2721, http://dx.doi.org/10.1182/blood.2022017814
2022
Aggarwal A; Stella AO; Walker G; Akerman A; Esneau C; Milogiannakis V; Burnett DL; McAllery S; Silva MR; Lu Y; Foster CSP; Brilot F; Pillay A; Van Hal S; Mathivanan V; Fichter C; Kindinger A; Hoppe AC; Munier ML; Amatayakul-Chantler S; Roth N; Coppola G; Symonds GP; Schofield P; Jackson J; Lenthall H; Henry JY; Mazigi O; Jäck HM; Davenport MP; Darley DR; Matthews GV; Khoury DS; Cromer D; Goodnow CC; Christ D; Robosa R; Starck DJ; Bartlett NW; Rawlinson WD; Kelleher AD; Turville SG, 2022, 'Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia', Nature Microbiology, 7, pp. 896 - 908, http://dx.doi.org/10.1038/s41564-022-01135-7
2022
Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks ML; Law H; Danwilai T; Starr M; Munier CML; Christ D; Singh M; Croucher PI; Brilot-Turville F; Turville S; Phan TG; Dore GJ; Darley D; Cunningham P; Matthews GV; Kelleher AD; Zaunders JJ, 2022, 'High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells', Frontiers in Immunology, 13, http://dx.doi.org/10.3389/fimmu.2022.1032911
2022
Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG, 2022, 'SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern', eBioMedicine, 84, http://dx.doi.org/10.1016/j.ebiom.2022.104270
2022
Shen Y; Freeman JA; Holland J; Solterbeck A; Naidu K; Soosapilla A; Downe P; Tang C; Kerridge I; Wallman L; Van Bilsen N; Milogiannakis V; Akerman A; Martins Costa Gomes G; Sandgren K; Cunningham AL; Turville S; Mulligan SP, 2021, COVID-19 Vaccine Failure in Chronic Lymphocytic Leukemia and Monoclonal B-Lymphocytosis; Humoral and Cellular Immunity, , http://dx.doi.org/10.1101/2021.10.28.21265549
2021

School of Medical Science (SoMS) Award for Safety Culture (MEDRIOS Team) (2020)

Nomination for UNSW Dean’s Award for Outstanding PhD Theses (2019)

Translational Cancer Research Network, PhD Scholarship Top-up Award (2018 – 2019)

European Pancreas Club Jubilee Meeting Travel Scholarship (2018)

Postgraduate Research Student Support Scheme (2018)

Prince of Wales Clinical School Travel Award (2018)

Campion-Ma-Playoust Memorial Award (Best Oral Presentation) Australian Society for Medical Research National Scientific Conference (2017)

Australian Postgraduate Award (APA) Scholarship (2015 – 2018)

Laboratory Efficiency Assessment Framework (LEAF) grant (2023)

This grant was awarded to the Kirby Institute LEAF team to establish a soft plastics recycling stream within the PC2 laboratory.

The focus of Nush's PhD (2015-2019) was understanding the metabolic changes that occur in pancreatic tumour cells and tumour-associated stromal cells, as these changes represent vulnerabilities that can be therapeutically targeted. Her PhD focused specifically on inhibiting various nutrient transporters, that are over-expressed in both cell types, using pharmacological inhibitors or gene therapy (nanoparticles coupled with siRNA). 

In 2021, Nush joined the Viral Pathogenesis and Vector Lab (VPVL) within the Immunovirology and Pathogenesis Program (IVPP) where she is involved in:

  • Collaborative testing of sera samples from convalescent or vaccinated donors
  • Screening of new antiviral SARS-CoV-2 drugs
  • Investigating SARS-CoV-2 viral tropism
  • Establishing platforms for testing Mpox